Evidence map›Paper›PMID 31874919›Full record

ArticlemBio2019

Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development?

Kristofer Wollein Waldetoft, James Gurney, Joseph Lachance, Paul A Hoskisson, Sam P Brown

Abstract read
In one paragraph

Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Alternate Antimicrobial Therapies and Their Companion Tests.Diagnostics (Basel, Switzerland) · 2023
    Review
  2. Evolving antibiotic spectrum.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kristofer Wollein WaldetoftSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia, USA kristofer.wolleinwaldetoft@biology.gatech.edu.
James GurneySchool of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia, USA.
Joseph LachanceSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia, USA.ORCID 0000-0002-4650-3741
Paul A HoskissonStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.ORCID 0000-0003-4332-1640
Sam P BrownSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To avoid an antibiotic resistance crisis, we need to develop antibiotics at a pace that matches the rate of evolution of resistance. However, the complex functions performed by antibiotics-combining, e.g., penetration of membranes, counteraction of resistance mechanisms, and interaction with molecular targets-have proven hard to achieve with current methods for drug development, including target-based screening and rational design. Here, we argue that we can meet the evolution of resistance in the clinic with evolution of antibiotics in the laboratory. On the basis of the results of experimental evolution studies of microbes in general and antibiotic production in

Indexed as

Biological ProductsDrug Resistance, MicrobialActinobacteriaAnti-Bacterial AgentsBacteriaDrug DevelopmentEvolution, MolecularAnti-Bacterial AgentsBiological Productsactinomycetesantibioticevolutionexperimental evolutionnatural antimicrobial products

Identifiers

PMID31874919
PMCPMC6935861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.